Loading...

Allison Brashear

Title(s)Dean, Dean's Office
SchoolUniversity of California, Davis
Address4610 X Street
CA 95817
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Cardiac phenotype in ATP1A3-related syndromes: A multicentre cohort study. Neurology. 2020 Sep 10. Balestrini S, Mikati MA, Garcia-Roves RA, Carboni M, Hunanyan AS, Kherallah B, McLean M, Prange L, De Grandis E, Gagliardi A, Pisciotta L, Stagnaro M, Veneselli E, Campistol J, Fons C, Pias-Peleteiro L, Brashear A, Miller C, Samoes R, Brankovic V, Padiath QS, Potic A, Pilch J, Vezyroglou K, Bye AME, Davis AM, Ryan MM, Semsarian C, Hollingsworth G, Scheffer IE, Granata T, Nardocci N, Ragona F, Arzimanoglou A, Panagiotakaki E, Carrilho I, Zucca C, Novy J, Dziezyc K, Parowicz M, Mazurkiewicz-Beldzinska M, Weckhuysen S, Pons R, Groppa S, Sinden DS, Pitt GS, Tinker A, Ashworth M, Michalak Z, Thom M, Cross JH, Vavassori R, Kaski JP, Sisodiya SM. PMID: 32913013.
      View in: PubMed   Mentions:    Fields:    
    2. The Effect of Repeated abobotulinumtoxinA (Dysport®) Injections on Walking Velocity in Persons with Spastic Hemiparesis Caused by Stroke or Traumatic Brain Injury. PM R. 2020 Aug 02. Esquenazi A, Brashear A, Deltombe T, Rudzinska-Bar M, Krawczyk M, Skoromets A, O'Dell MW, Grandoulier AS, Vilain C, Picaut P, Gracies JM. PMID: 32741133.
      View in: PubMed   Mentions:    Fields:    
    3. Efficacy and Safety of AbobotulinumtoxinA for the Treatment of Hemiparesis in Adults with Lower Limb Spasticity Previously Treated With Other Botulinum Toxins: A Secondary Analysis of a Randomized Controlled Trial. PM R. 2020 09; 12(9):853-860. Esquenazi A, Stoquart G, Hedera P, Jacinto LJ, Dimanico U, Constant-Boyer F, Brashear A, Grandoulier AS, Vilain C, Picaut P, Gracies JM. PMID: 32108436.
      View in: PubMed   Mentions:    Fields:    
    4. IncobotulinumtoxinA Treatment in Upper-Limb Poststroke Spasticity in the Open-Label Extension Period of PURE: Efficacy in Passive Function, Caregiver Burden, and Quality of Life. PM R. 2020 05; 12(5):491-499. Marciniak C, Munin MC, Brashear A, Rubin BS, Patel AT, Slawek J, Hanschmann A, Hiersemenzel R, Elovic EP. PMID: 31647185.
      View in: PubMed   Mentions:    Fields:    
    5. Saving neurology: Once more with feeling. Neurology. 2019 12 03; 93(23):989-990. Schor NF, Brashear A. PMID: 31690683.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    6. Factors in the disease severity of ATP1A3 mutations: Impairment, misfolding, and allele competition. Neurobiol Dis. 2019 12; 132:104577. Arystarkhova E, Haq IU, Luebbert T, Mochel F, Saunders-Pullman R, Bressman SB, Feschenko P, Salazar C, Cook JF, Demarest S, Brashear A, Ozelius LJ, Sweadner KJ. PMID: 31425744.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    7. Revising rapid-onset dystonia-parkinsonism: Broadening indications for ATP1A3 testing. Mov Disord. 2019 10; 34(10):1528-1536. Haq IU, Snively BM, Sweadner KJ, Suerken CK, Cook JF, Ozelius LJ, Miller C, McCall WV, Whitlow CT, Brashear A. PMID: 31361359.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    8. Alternating Hemiplegia of Childhood in a Person of Malay Ethnicity with Diffusion Tensor Imaging Abnormalities. J Mov Disord. 2019 May; 12(2):132-134. Tan AH, Ong TL, Ramli N, Tan LK, Lim JL, Azhan MA, Ahmad-Annuar A, Ibrahim KA, Abdul-Aziz Z, Ozelius LJ, Brashear A, Lim SY. PMID: 31158946.
      View in: PubMed   Mentions:
    9. Genotype-structure-phenotype relationships diverge in paralogs ATP1A1, ATP1A2, and ATP1A3. Neurol Genet. 2019 Feb; 5(1):e303. Sweadner KJ, Arystarkhova E, Penniston JT, Swoboda KJ, Brashear A, Ozelius LJ. PMID: 30842972.
      View in: PubMed   Mentions:
    10. IncobotulinumtoxinA Efficacy and Safety in Adults with Upper-Limb Spasticity Following Stroke: Results from the Open-Label Extension Period of a Phase 3 Study. Adv Ther. 2019 01; 36(1):187-199. Marciniak C, Munin MC, Brashear A, Rubin BS, Patel AT, Slawek J, Hanschmann A, Hiersemenzel R, Elovic EP. PMID: 30484117.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    11. Burnout in neurology: Extinguishing the embers and rekindling the joy in practice. Neurology. 2018 11 13; 91(20):907-908. Brashear A, Vickrey BG. PMID: 30305444.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    12. Gender bias in American Academy of Neurology recognition awards? Neurology. 2018 08 14; 91(7):291-292. Graves JS, Brashear A. PMID: 30030327.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    13. Injectable DaxibotulinumtoxinA in Cervical Dystonia: A Phase 2 Dose-Escalation Multicenter Study. Mov Disord Clin Pract. 2018 May-Jun; 5(3):273-282. Jankovic J, Truong D, Patel AT, Brashear A, Evatt M, Rubio RG, Oh CK, Snyder D, Shears G, Comella C. PMID: 30009213.
      View in: PubMed   Mentions:
    14. A 500 U/2 mL dilution of abobotulinumtoxinA vs. placebo: randomized study in cervical dystonia. Int J Neurosci. 2018 Jul; 128(7):619-626. Lew MF, Brashear A, Dashtipour K, Isaacson S, Hauser RA, Maisonobe P, Snyder D, Ondo W. PMID: 29343142.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    15. Efficacy and safety of abobotulinumtoxinA in spastic lower limb: Randomized trial and extension. Neurology. 2017 Nov 28; 89(22):2245-2253. Gracies JM, Esquenazi A, Brashear A, Banach M, Kocer S, Jech R, Khatkova S, Benetin J, Vecchio M, McAllister P, Ilkowski J, Ochudlo S, Catus F, Grandoulier AS, Vilain C, Picaut P. PMID: 29093068.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    16. Rehabilitation plus OnabotulinumtoxinA Improves Motor Function over OnabotulinumtoxinA Alone in Post-Stroke Upper Limb Spasticity: A Single-Blind, Randomized Trial. Toxins (Basel). 2017 07 11; 9(7). Devier D, Harnar J, Lopez L, Brashear A, Graham G. PMID: 28696373.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    17. Dose-Dependent Effects of AbobotulinumtoxinA (Dysport) on Spasticity and Active Movements in Adults With Upper Limb Spasticity: Secondary Analysis of a Phase 3 Study. PM R. 2018 01; 10(1):1-10. O'Dell MW, Brashear A, Jech R, Lejeune T, Marque P, Bensmail D, Ayyoub Z, Simpson DM, Volteau M, Vilain C, Picaut P, Gracies JM. PMID: 28634000.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    18. Efficacy and Safety of AbobotulinumtoxinA (Dysport) for the Treatment of Hemiparesis in Adults With Upper Limb Spasticity Previously Treated With Botulinum Toxin: Subanalysis From a Phase 3 Randomized Controlled Trial. PM R. 2017 12; 9(12):1181-1190. Marciniak C, McAllister P, Walker H, Brashear A, Edgley S, Deltombe T, Khatkova S, Banach M, Gul F, Vilain C, Picaut P, Grandoulier AS, Gracies JM. PMID: 28625615.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    19. Head drop after botox: Electrodiagnostic evaluation of iatrogenic botulinum toxicity. Clin Neurol Neurosurg. 2017 May; 156:1-3. Szuch E, Caress JB, Paudyal B, Brashear A, Cartwright MS, Strowd RE. PMID: 28273554.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    20. Research conference summary from the 2014 International Task Force on ATP1A3-Related Disorders. Neurol Genet. 2017 Apr; 3(2):e139. Rosewich H, Sweney MT, DeBrosse S, Ess K, Ozelius L, Andermann E, Andermann F, Andrasco G, Belgrade A, Brashear A, Ciccodicola S, Egan L, George AL, Lewelt A, Magelby J, Merida M, Newcomb T, Platt V, Poncelin D, Reyna S, Sasaki M, Sotero de Menezes M, Sweadner K, Viollet L, Zupanc M, Silver K, Swoboda K. PMID: 28293679.
      View in: PubMed   Mentions:
    21. Poster 289 Patient Registry of Spasticity Care World Data Analysis Based on Physician Experience. PM R. 2016 Sep; 8(9S):S254. Esquenazi A, Lee S, Mayer NH, Brashear A, Francisco GE, Yablon EE, Garreta R, Wissel J, Molteni F. PMID: 27673047.
      View in: PubMed   Mentions:    Fields:    
    22. Poster 288 Efficacy and Safety of Repeated AbobotulinumtoxinA Injections in Adults with Lower Limb Spasticity. PM R. 2016 Sep; 8(9S):S254. Gracies JM, Esquenazi A, Brashear A, Edgley SR, O'Dell M, Hedera P, Rubin BS, Picaut P. PMID: 27673046.
      View in: PubMed   Mentions:    Fields:    
    23. ATP1A3 Mutation in Adult Rapid-Onset Ataxia. PLoS One. 2016; 11(3):e0151429. Sweadner KJ, Toro C, Whitlow CT, Snively BM, Cook JF, Ozelius LJ, Markello TC, Brashear A. PMID: 26990090.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    24. A dystonia-like movement disorder with brain and spinal neuronal defects is caused by mutation of the mouse laminin ß1 subunit, Lamb1. Elife. 2015 Dec 24; 4. Liu YB, Tewari A, Salameh J, Arystarkhova E, Hampton TG, Brashear A, Ozelius LJ, Khodakhah K, Sweadner KJ. PMID: 26705335.
      View in: PubMed   Mentions: 7     Fields:    Translation:Animals
    25. Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double-blind randomised controlled trial. Lancet Neurol. 2015 Oct; 14(10):992-1001. Gracies JM, Brashear A, Jech R, McAllister P, Banach M, Valkovic P, Walker H, Marciniak C, Deltombe T, Skoromets A, Khatkova S, Edgley S, Gul F, Catus F, De Fer BB, Vilain C, Picaut P. PMID: 26318836.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    26. Novel mutations in ATP1A3 associated with catastrophic early life epilepsy, episodic prolonged apnea, and postnatal microcephaly. Epilepsia. 2015 Mar; 56(3):422-30. Paciorkowski AR, McDaniel SS, Jansen LA, Tully H, Tuttle E, Ghoneim DH, Tupal S, Gunter SA, Vasta V, Zhang Q, Tran T, Liu YB, Ozelius LJ, Brashear A, Sweadner KJ, Dobyns WB, Hahn S. PMID: 25656163.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCells
    27. Rapid-Onset Dystonia-Parkinsonism in a Chinese Girl with a De Novo ATP1A3 c.2267G>A (p.R756H) Genetic Mutation. Mov Disord Clin Pract. 2015 Mar; 2(1):74-75. Tan AH, Ozelius LJ, Brashear A, Lang AE, Ahmad-Annuar A, Tan CT, Lim SY. PMID: 30713883.
      View in: PubMed   Mentions:
    28. Rapid-onset dystonia-parkinsonism associated with the I758S mutation of the ATP1A3 gene: a neuropathologic and neuroanatomical study of four siblings. Acta Neuropathol. 2014 Jul; 128(1):81-98. Oblak AL, Hagen MC, Sweadner KJ, Haq I, Whitlow CT, Maldjian JA, Epperson F, Cook JF, Stacy M, Murrell JR, Ozelius LJ, Brashear A, Ghetti B. PMID: 24803225.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    29. Distinct neurological disorders with ATP1A3 mutations. Lancet Neurol. 2014 May; 13(5):503-14. Heinzen EL, Arzimanoglou A, Brashear A, Clapcote SJ, Gurrieri F, Goldstein DB, Jóhannesson SH, Mikati MA, Neville B, Nicole S, Ozelius LJ, Poulsen H, Schyns T, Sweadner KJ, van den Maagdenberg A, Vilsen B. PMID: 24739246.
      View in: PubMed   Mentions: 67     Fields:    Translation:HumansAnimals
    30. Heterogeneity in primary dystonia: lessons from THAP1, GNAL, and TOR1A in Amish-Mennonites. Mov Disord. 2014 May; 29(6):812-8. Saunders-Pullman R, Fuchs T, San Luciano M, Raymond D, Brashear A, Ortega R, Deik A, Ozelius LJ, Bressman SB. PMID: 24500857.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    31. Cognitive impairment in rapid-onset dystonia-parkinsonism. Mov Disord. 2014 Mar; 29(3):344-50. Cook JF, Hill DF, Snively BM, Boggs N, Suerken CK, Haq I, Stacy M, McCall WV, Ozelius LJ, Sweadner KJ, Brashear A. PMID: 24436111.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    32. ATP1A3 mutations: what is the phenotype? Neurology. 2014 Feb 11; 82(6):468-9. Brashear A, Ozelius LJ, Sweadner KJ. PMID: 24431297.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    33. Commentary. Mov Disord. 2013 Dec; 28(14):1939. Brashear A. PMID: 24323532.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    34. Coding for the use of botulinum toxin for movement disorders. Continuum (Minneap Minn). 2013 Oct; 19(5 Movement Disorders):1406-15. Brashear A, Bushong L. PMID: 24092297.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    35. Treatment of cervical dystonia. Expert Opinion on Orphan Drugs. 2013 Oct 1; 1(8):599-606. Allison Brashear. .
      View in: Publisher Site   Mentions:
    36. A randomized, double-blind study of repeated incobotulinumtoxinA (Xeomin(®)) in cervical dystonia. J Neural Transm (Vienna). 2013 Dec; 120(12):1699-707. Evidente VG, Fernandez HH, LeDoux MS, Brashear A, Grafe S, Hanschmann A, Comella CL. PMID: 23779062.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    37. Cost-effectiveness of onabotulinumtoxinA for the treatment of wrist and hand disability due to upper-limb post-stroke spasticity in Scotland. Eur J Neurol. 2013 May; 20(5):773-80. Doan QV, Gillard P, Brashear A, Halperin M, Hayward E, Varon S, Lu ZJ. PMID: 23278954.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    38. Patient registry of outcomes in spasticity care. Am J Phys Med Rehabil. 2012 Sep; 91(9):729-46. Esquenazi A, Mayer N, Lee S, Brashear A, Elovic E, Francisco GE, Yablon S. PMID: 22469872.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    39. Efficacy, tolerability, and immunogenicity of onabotulinumtoxina in a randomized, double-blind, placebo-controlled trial for cervical dystonia. Clin Neuropharmacol. 2012 Sep-Oct; 35(5):208-14. Charles D, Brashear A, Hauser RA, Li HI, Boo LM, Brin MF. PMID: 22948497.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCTClinical Trials
    40. Psychiatric disorders in rapid-onset dystonia-parkinsonism. Neurology. 2012 Sep 11; 79(11):1168-73. Brashear A, Cook JF, Hill DF, Amponsah A, Snively BM, Light L, Boggs N, Suerken CK, Stacy M, Ozelius L, Sweadner KJ, McCall WV. PMID: 22933743.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    41. ATP1A3 mutations in infants: a new rapid-onset dystonia-Parkinsonism phenotype characterized by motor delay and ataxia. Dev Med Child Neurol. 2012 Nov; 54(11):1065-7. Brashear A, Mink JW, Hill DF, Boggs N, McCall WV, Stacy MA, Snively B, Light LS, Sweadner KJ, Ozelius LJ, Morrison L. PMID: 22924536.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    42. New triggers and non-motor findings in a family with rapid-onset dystonia-parkinsonism. Parkinsonism Relat Disord. 2012 Jul; 18(6):737-41. Barbano RL, Hill DF, Snively BM, Light LS, Boggs N, McCall WV, Stacy M, Ozelius L, Sweadner KJ, Brashear A. PMID: 22534615.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    43. Relationship between disability and health-related quality of life and caregiver burden in patients with upper limb poststroke spasticity. PM R. 2012 Jan; 4(1):4-10. Doan QV, Brashear A, Gillard PJ, Varon SF, Vandenburgh AM, Turkel CC, Elovic EP. PMID: 22200567.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    44. Comment: The new mentoring and team leadership. Neurology. 2011 Aug 16; 77(7):685. Brashear A. PMID: 21795648.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    45. A diagnostic test to distinguish psychogenic dystonia from organic dystonia? Neurology. 2011 Feb 15; 76(7):590-1. Chen R, Brashear A. PMID: 21321331.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    46. Botulinum toxin type A: Exploring new indications. Drugs Today (Barc). 2010 Sep; 46(9):671-82. Brashear A. PMID: 20967299.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    47. Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia. Parkinsonism Relat Disord. 2010 Jun; 16(5):316-23. Truong D, Brodsky M, Lew M, Brashear A, Jankovic J, Molho E, Orlova O, Timerbaeva S. PMID: 20359934.
      View in: PubMed   Mentions: 38     Fields:    Translation:Humans
    48. Botulinum toxin type A in the treatment of patients with cervical dystonia. Biologics. 2009; 3:1-7. Brashear A. PMID: 19707390.
      View in: PubMed   Mentions:
    49. Spasticity. Curr Treat Options Neurol. 2009 May; 11(3):153-61. Brashear A, Lambeth K. PMID: 19364449.
      View in: PubMed   Mentions:
    50. Botulinum neurotoxin versus tizanidine in upper limb spasticity: a placebo-controlled study. J Neurol Neurosurg Psychiatry. 2009 Apr; 80(4):380-5. Simpson DM, Gracies JM, Yablon SA, Barbano R, Brashear A. PMID: 18977811.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    51. Clinical comparisons of botulinum neurotoxin formulations. Neurologist. 2008 Sep; 14(5):289-98. Brashear A. PMID: 18784598.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimals
    52. Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Mov Disord. 2008 Jul 30; 23(10):1353-60. Brin MF, Comella CL, Jankovic J, Lai F, Naumann M. PMID: 18546321.
      View in: PubMed   Mentions: 47     Fields:    Translation:HumansAnimalsCTClinical Trials
    53. Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008 May 06; 70(19):1699-706. Simpson DM, Blitzer A, Brashear A, Comella C, Dubinsky R, Hallett M, Jankovic J, Karp B, Ludlow CL, Miyasaki JM, Naumann M, So Y. PMID: 18458230.
      View in: PubMed   Mentions: 116     Fields:    Translation:Humans
    54. Repeated treatments with botulinum toxin type a produce sustained decreases in the limitations associated with focal upper-limb poststroke spasticity for caregivers and patients. Arch Phys Med Rehabil. 2008 May; 89(5):799-806. Elovic EP, Brashear A, Kaelin D, Liu J, Millis SR, Barron R, Turkel C. PMID: 18452724.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    55. Formation of neutralizing antibodies in patients receiving botulinum toxin type A for treatment of poststroke spasticity: a pooled-data analysis of three clinical trials. Clin Ther. 2007 Apr; 29(4):683-90. Yablon SA, Brashear A, Gordon MF, Elovic EP, Turkel CC, Daggett S, Liu J, Brin MF. PMID: 17617291.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    56. The phenotypic spectrum of rapid-onset dystonia-parkinsonism (RDP) and mutations in the ATP1A3 gene. Brain. 2007 Mar; 130(Pt 3):828-35. Brashear A, Dobyns WB, de Carvalho Aguiar P, Borg M, Frijns CJ, Gollamudi S, Green A, Guimaraes J, Haake BC, Klein C, Linazasoro G, Münchau A, Raymond D, Riley D, Saunders-Pullman R, Tijssen MA, Webb D, Zaremba J, Bressman SB, Ozelius LJ. PMID: 17282997.
      View in: PubMed   Mentions: 63     Fields:    Translation:Humans
    57. Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia. Neurology. 2006 Dec 26; 67(12):2233-5. Jankovic J, Hunter C, Dolimbek BZ, Dolimbek GS, Adler CH, Brashear A, Comella CL, Gordon M, Riley DE, Sethi K, Singer C, Stacy M, Tarsy D, Atassi MZ. PMID: 17190952.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    58. The safety and tolerability of botulinum toxins for the treatment of cervical dystonia. Expert Opin Drug Saf. 2005 Mar; 4(2):241-9. Brashear A. PMID: 15794717.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    59. Chapter L1 Spasticity. . 2005 Jan 1; (Arch Phys Med Rehab7511994):679-686. Allison Brashear. .
      View in: Publisher Site   Mentions:
    60. Longitudinal assessment of the dose consistency of botulinum toxin type A (BOTOX) for cervical dystonia. Adv Ther. 2005 Jan-Feb; 22(1):49-55. Brashear A, Hogan P, Wooten-Watts M, Marchetti A, Magar R, Martin J. PMID: 15943222.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    61. Rapid-onset dystonia-parkinsonism: a fourth family consistent with linkage to chromosome 19q13. Mov Disord. 2004 Dec; 19(12):1506-10. Zaremba J, Mierzewska H, Lysiak Z, Kramer P, Ozelius LJ, Brashear A. PMID: 15390049.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    62. Dopamine transporter density in schizophrenic subjects with and without tardive dyskinesia. Schizophr Res. 2004 Dec 01; 71(2-3):371-5. Yoder KK, Hutchins GD, Morris ED, Brashear A, Wang C, Shekhar A. PMID: 15474908.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    63. Repeated dosing of botulinum toxin type A for upper limb spasticity following stroke. Neurology. 2004 Nov 23; 63(10):1971-3. Gordon MF, Brashear A, Elovic E, Kassicieh D, Marciniak C, Liu J, Turkel C. PMID: 15557529.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCTClinical Trials
    64. Mutations in the Na+/K+ -ATPase alpha3 gene ATP1A3 are associated with rapid-onset dystonia parkinsonism. Neuron. 2004 Jul 22; 43(2):169-75. de Carvalho Aguiar P, Sweadner KJ, Penniston JT, Zaremba J, Liu L, Caton M, Linazasoro G, Borg M, Tijssen MA, Bressman SB, Dobyns WB, Brashear A, Ozelius LJ. PMID: 15260953.
      View in: PubMed   Mentions: 142     Fields:    Translation:HumansCells
    65. Dose-dependent response to intramuscular botulinum toxin type A for upper-limb spasticity in patients after a stroke. Arch Phys Med Rehabil. 2004 Jul; 85(7):1063-9. Childers MK, Brashear A, Jozefczyk P, Reding M, Alexander D, Good D, Walcott JM, Jenkins SW, Turkel C, Molloy PT. PMID: 15241751.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCTClinical Trials
    66. Refined linkage to the RDP/DYT12 locus on 19q13.2 and evaluation of GRIK5 as a candidate gene. Mov Disord. 2004 Jul; 19(7):845-847. Kamm C, Leung J, Joseph S, Dobyns WB, Brashear A, Breakefield XO, Ozelius LJ. PMID: 15254951.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    67. Treatment of cervical dystonia with botulinum toxin. Operative Techniques in Otolaryngology-Head and Neck Surgery. 2004 Jun 1; 15(2):122-127. Allison Brashear. .
      View in: Publisher Site   Mentions:
    68. Botulinum toxin type B in upper-limb poststroke spasticity: a double-blind, placebo-controlled trial. Arch Phys Med Rehabil. 2004 May; 85(5):705-9. Brashear A, McAfee AL, Kuhn ER, Fyffe J. PMID: 15129392.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    69. Use of botulinum toxin type A in poststroke spasticity. Expert Rev Neurother. 2003 May; 3(3):271-7. Brashear A. PMID: 19810893.
      View in: PubMed   Mentions:    Fields:    
    70. Botulinum toxin for spasticity after stroke. N Engl J Med. 2003 Jan 16; 348(3):258-9; author reply 258-9. Dobkin BH. PMID: 12530439.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    71. Treatment with botulinum toxin type B for upper-limb spasticity. Arch Phys Med Rehabil. 2003 Jan; 84(1):103-7. Brashear A, McAfee AL, Kuhn ER, Ambrosius WT. PMID: 12589629.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    72. Inter- and intrarater reliability of the Ashworth Scale and the Disability Assessment Scale in patients with upper-limb poststroke spasticity. Arch Phys Med Rehabil. 2002 Oct; 83(10):1349-54. Brashear A, Zafonte R, Corcoran M, Galvez-Jimenez N, Gracies JM, Gordon MF, McAfee A, Ruffing K, Thompson B, Williams M, Lee CH, Turkel C. PMID: 12370866.
      View in: PubMed   Mentions: 38     Fields:    Translation:HumansCTClinical Trials
    73. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med. 2002 Aug 08; 347(6):395-400. Brashear A, Gordon MF, Elovic E, Kassicieh VD, Marciniak C, Do M, Lee CH, Jenkins S, Turkel C. PMID: 12167681.
      View in: PubMed   Mentions: 90     Fields:    Translation:HumansCTClinical Trials
    74. Botulinum toxin type B: a new injectable treatment for cervical dystonia. Expert Opin Investig Drugs. 2001 Dec; 10(12):2191-9. Brashear A. PMID: 11772315.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimals
    75. Cervical dystonia severity scale reliability study. Mov Disord. 2001 Nov; 16(6):1086-90. O'Brien C, Brashear A, Cullis P, Truong D, Molho E, Jenkins S, Wojcieszek J, O'Neil T, Factor S, Seeberger L. PMID: 11748739.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    76. Botulinum toxin type a neuromuscular blockade in the treatment of equinus foot deformity in cerebral palsy: a multicenter, open-label clinical trial. Pediatrics. 2001 Nov; 108(5):1062-71. Koman LA, Brashear A, Rosenfeld S, Chambers H, Russman B, Rang M, Root L, Ferrari E, Garcia de Yebenes Prous J, Smith BP, Turkel C, Walcott JM, Molloy PT. PMID: 11694682.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCTClinical Trials
    77. The botulinum toxins in the treatment of cervical dystonia. Semin Neurol. 2001; 21(1):85-90. Brashear A. PMID: 11346029.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    78. Duration of effect of botulinum toxin type A in adult patients with cervical dystonia: a retrospective chart review. Clin Ther. 2000 Dec; 22(12):1516-24. Brashear A, Watts MW, Marchetti A, Magar R, Lau H, Wang L. PMID: 11192142.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    79. Patients' perception of stopping or continuing treatment of cervical dystonia with botulinum toxin type A. Mov Disord. 2000 Jan; 15(1):150-3. Brashear A, Bergan K, Wojcieszek J, Siemers ER, Ambrosius W. PMID: 10634256.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    80. The safety and efficacy of botulinum toxin type B in the treatment of patients with cervical dystonia: summary of three controlled clinical trials. Neurology. 2000; 55(12 Suppl 5):S29-35. Lew MF, Brashear A, Factor S. PMID: 11188982.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    81. Metrifonate treatment of AD: influence of APOE genotype. Neurology. 1999 Dec 10; 53(9):2010-6. Farlow MR, Cyrus PA, Nadel A, Lahiri DK, Brashear A, Gulanski B. PMID: 10599773.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    82. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology. 1999 Oct 22; 53(7):1439-46. Brashear A, Lew MF, Dykstra DD, Comella CL, Factor SA, Rodnitzky RL, Trosch R, Singer C, Brin MF, Murray JJ, Wallace JD, Willmer-Hulme A, Koller M. PMID: 10534248.
      View in: PubMed   Mentions: 43     Fields:    Translation:HumansCTClinical Trials
    83. Rapid-onset dystonia-parkinsonism: linkage to chromosome 19q13. Ann Neurol. 1999 Aug; 46(2):176-82. Kramer PL, Mineta M, Klein C, Schilling K, de Leon D, Farlow MR, Breakefield XO, Bressman SB, Dobyns WB, Ozelius LJ, Brashear A. PMID: 10443882.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    84. Rapid onset dystonia-parkinsonism in a 14-year-old girl. Eur J Paediatr Neurol. 1999; 3(4):171-3. Webb DW, Broderick A, Brashear A, Dobyns WB. PMID: 10476366.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    85. PET imaging of the pre-synaptic dopamine uptake sites in rapid-onset dystonia-parkinsonism (RDP). Mov Disord. 1999 Jan; 14(1):132-7. Brashear A, Mulholland GK, Zheng QH, Farlow MR, Siemers ER, Hutchins GD. PMID: 9918356.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    86. Impaired traffic sign recognition in drivers with dementia. American Journal of Alzheimer's Disease & Other Dementias®. 1998 May 1; 13(3):131-137. Allison Brashear, Frederick W. Unverzagt, Elizabeth R. Kuhn, Bradley S. Glazier, Martin R. Farlow, Anthony J. Perkins, Siu L. Hui. .
      View in: Publisher Site   Mentions:
    87. Cerebrospinal fluid homovanillic acid levels in rapid-onset dystonia-parkinsonism. Ann Neurol. 1998 Apr; 43(4):521-6. Brashear A, Butler IJ, Hyland K, Farlow MR, Dobyns WB. PMID: 9546335.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    88. Rapid-onset dystonia-parkinsonism: a report of clinical, biochemical, and genetic studies in two families. Adv Neurol. 1998; 78:335-9. Brashear A, Butler IJ, Ozelius LJ, Kramer PI, Farlow MR, Breakefield XO, Dobyns WB. PMID: 9750930.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    89. Comparison of treatment of tardive dystonia and idiopathic cervical dystonia with botulinum toxin type A. Mov Disord. 1998 Jan; 13(1):158-61. Brashear A, Ambrosius WT, Eckert GJ, Siemers ER. PMID: 9452343.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    90. Costs of treating dystonias and hemifacial spasm with botulinum toxin A. Pharmacoeconomics. 1997 Dec; 12(6):695-706. Dodel RC, Kirchner A, Koehne-Volland R, Künig G, Ceballos-Baumann A, Naumann M, Brashear A, Richter HP, Szucs TD, Oertel WH. PMID: 10175981.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    91. Focal dystonia after chemotherapy: a case series. J Neurooncol. 1997 Sep; 34(2):163-7. Brashear A, Siemers E. PMID: 9210064.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    92. Rapid-onset dystonia-parkinsonism in a second family. Neurology. 1997 Apr; 48(4):1066-9. Brashear A, DeLeon D, Bressman SB, Thyagarajan D, Farlow MR, Dobyns WB. PMID: 9109901.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    93. Ethylene oxide neurotoxicity: a cluster of 12 nurses with peripheral and central nervous system toxicity. Neurology. 1996 Apr; 46(4):992-8. Brashear A, Unverzagt FW, Farber MO, Bonnin JM, Garcia JG, Grober E. PMID: 8780078.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    94. Variable phenotype of rapid-onset dystonia-parkinsonism. Mov Disord. 1996 Mar; 11(2):151-6. Brashear A, Farlow MR, Butler IJ, Kasarskis EJ, Dobyns WB. PMID: 8684384.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    95. The influence of the reference electrode on CMAP configuration: leg nerve observations and an alternative reference site. Muscle Nerve. 1996 Jan; 19(1):63-7. Brashear A, Kincaid JC. PMID: 8538671.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    96. Prevalence of Alzheimer's disease and dementia in two communities: Nigerian Africans and African Americans. Am J Psychiatry. 1995 Oct; 152(10):1485-92. Hendrie HC, Osuntokun BO, Hall KS, Ogunniyi AO, Hui SL, Unverzagt FW, Gureje O, Rodenberg CA, Baiyewu O, Musick BS. PMID: 7573588.
      View in: PubMed   Mentions: 104     Fields:    Translation:Humans
    97. Percutaneous celiac plexus block with botulinum toxin A did not help the pain of chronic pancreatitis. J Clin Gastroenterol. 1995 Jun; 20(4):343-4. Sherman S, Kopecky KK, Brashear A, Lehman GA. PMID: 7665834.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    98. Apolipoprotein E genotypes and Alzheimer's disease in a community study of elderly African Americans. Ann Neurol. 1995 Jan; 37(1):118-20. Hendrie HC, Hall KS, Hui S, Unverzagt FW, Yu CE, Lahiri DK, Sahota A, Farlow M, Musick B, Class CA. PMID: 7818244.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    99. Cross-national interrater agreement on the clinical diagnostic criteria for dementia. WHO-PRA Age-Associated Dementia Working Group, WHO-Program for Research on Aging, Health of Elderly Program. Neurology. 1994 Feb; 44(2):239-42. Baldereschi M, Amato MP, Nencini P, Pracucci G, Lippi A, Amaducci L, Gauthier S, Beatty L, Quiroga P, Klassen G. PMID: 8309565.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    100. Rapid-onset dystonia-parkinsonism. Neurology. 1993 Dec; 43(12):2596-602. Dobyns WB, Ozelius LJ, Kramer PL, Brashear A, Farlow MR, Perry TR, Walsh LE, Kasarskis EJ, Butler IJ, Breakefield XO. PMID: 8255463.
      View in: PubMed   Mentions: 31     Fields:    Translation:Humans
    101. The influence of the reference electrode on CMAP configuration. Muscle Nerve. 1993 Apr; 16(4):392-6. Kincaid JC, Brashear A, Markand ON. PMID: 8455652.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    102. Takayasu's Arteritis and Multiple Sclerosis. Journal of Neuroimaging. 1992 Jan 1; 2(1):36-38. Allison Brashear, Robert M. Pascuzzi. .
      View in: Publisher Site   Mentions:
    103. The ventilatory response to intravenous and ventriculo-cisternal theophylline. Res Commun Chem Pathol Pharmacol. 1983 Jul; 41(1):79-94. Wick JE, DeAtley RE, Oei TO, Glick MR, Brashear A, Baenziger J, Brashear RE. PMID: 6622832.
      View in: PubMed   Mentions:    Fields:    Translation:Animals
    104. A spectrophotometric, enzymatic assay for D-3-hydroxybutyrate that is not dependent on hydrazine. Anal Biochem. 1983 Jun; 131(2):478-82. Brashear A, Cook GA. PMID: 6614481.
      View in: PubMed   Mentions: 3     Fields:    Translation:Animals
    Allison's Networks
    Concepts (341)
    Derived automatically from this person's publications.
    _
    Co-Authors (2)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _